Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer

Ching-Feng Wu, Jui-Ying Fu, Chi-Ju Yeh, Yun-Hen Liu, Ming-Ju Hsieh, Yi-Cheng Wu, Ching-Yang Wu, Ying-Huang Tsai, Wen-Chi Chou, Ching-Feng Wu, Jui-Ying Fu, Chi-Ju Yeh, Yun-Hen Liu, Ming-Ju Hsieh, Yi-Cheng Wu, Ching-Yang Wu, Ying-Huang Tsai, Wen-Chi Chou

Abstract

Lung cancer is the leading cause of cancer-related death worldwide. Even early-stage patients might encounter disease recurrence with relative high risk. Effective postoperative therapy is based on an accurate assessment of treatment failure after surgery. The aim of this study is to construct a disease-free survival (DFS) prediction model and stratify patients into different risk score groups.A total of 356 pathological stage I patients (7th American Joint Committee on Cancer) who underwent lung resection from January 2005 through June 2011 were retrospectively reviewed. Of these patients, 63 patients were eliminated for this study. A total of 293 p-stage I patients were included for further univariate and multivariate analysis. Clinical, surgical, and pathological factors associated with high risk of recurrence were analyzed, including age, gender, smoking status, additional primary malignancy (APM), operation method, histology, visceral pleural invasion, angiolymphatic invasion, tumor necrosis, and tumor size.Of the 293 p-stage I non-small cell lung cancer (NSCLC) patients examined, 143 were female and 150 were male, with a mean age of 62.8-years old (range: 25-83-years old). The 5-year DFS and overall survival rates after surgery were 58.9% and 75.3%, respectively. On multivariate analysis, current smoker (hazards ratio [HR]: 1.63), APM (HR: 1.86), tumor size (HR: 1.54, 2.03), nonanatomic resections (HR: 1.81), adenocarcinoma histology (HR: 2.07), visceral pleural invasion (HR: 1.54), and angiolymphatic invasion (HR: 1.53) were found to be associated with a higher risk of tumor recurrence. The final model showed a fair discrimination ability (C-statistic = 0.68). According to the difference risk group, we found patients with intermediate or higher risk group had a higher distal relapse tendency as compared with low risk group (P = 0.016, odds ratio: 3.31, 95% confidence interval: 1.21-9.03).Greater than 30% of disease recurrences occurred after surgery for stage I NSCLC patients. That is why we try to establish an effective DFS predicting model based on clinical, pathological, and surgical covariates. However, our initial results still need to be validated and refined into greater population for better application in clinical use.

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Disease-free survival rates of stage I patients with different pT status (P < 0.001).
FIGURE 2
FIGURE 2
Disease-free survival rates for different risk group (P < 0.001).
FIGURE 3
FIGURE 3
Relapse site analysis with risk score (P = 0.016, odds ratio: 3.31, 95% confidence interval [CI]: 1.21–9.03).

References

    1. American Joint Committee on Cancer (AJCC) cancer staging handbook. In: Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual. 7th ed. Chicago: Springer; 2010:299–323.
    1. National comprehensive cancer network guideline version 2. 2013.
    1. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung. Cancer 2009; 115:5218–5227.
    1. Guerreraa F, Erricob L, Evangelistac A, et al. Exploring stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resection. Eur J Cardiothorac Surg 2014; 6:1037–1043.
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552–3559.
    1. Tsutani Y, Miyata Y, Kushitani K, et al. Propensity score-matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer. J Thorac Cardiovasc Surg 2014; 148:1179–1185.
    1. Kato H, Ichinose Y, Ohta M, et al. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713–1721.
    1. Hamada C, Tsuboi M, Ohta M, et al. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol 2009; 4:1511–1516.
    1. Tanaka F, Wada H, Fukushima M. UFT and S-1 for treatment of primary lung cancer. Gen Thorac Cardiovasc Surg 2010; 58:3–13.
    1. Travis WD, Brambilla E, Rami-Porta R, et al. International Staging Committee. Visceral pleural invasion: pathologic criteria and use of elastic stains. Proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol 2008; 3:1384–1390.
    1. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130:160–165.
    1. Schuchert MJ, Schumacher L, Kilic A, et al. Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. Ann Thorac Surg 2011; 91:1059–1065.
    1. Kato T, Ishikawa K, Aragaki M, et al. Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer 2012; 77:394–400.
    1. Arame A, Mordant P, Cazes A, et al. Characteristics and prognostic value of lymphatic and blood vascular microinvasion in lung cancer. Ann Thorac Surg 2012; 94:1673–1679.10.
    1. Park SY, Lee HS, Jang HJ, et al. Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. Ann Thorac Surg 2011; 91:1668–1673.
    1. Riquet M, Legras A, Mordant P, et al. Number of mediastinal lymph nodes in non-small cell lung cancer: a gaussian curve, not a prognostic factor. Ann Thorac Surg 2014; 98:224–231.
    1. Chang MY, Mentzer J, Colson YL, et al. Factors predicting poor survival after resection of stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 134:850–856.
    1. Asamura H, Goya T, Koshiishi Y, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008; 3:46–52.
    1. Peters S, Weder W, Dafni U, et al. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol 2014; 9:1675–1684.
    1. Son C, Lee SK, Choi PJ, et al. Characteristics of additional primary malignancies in Korean patients with non-small cell lung cancer. J Thorac Dis 2013; 5:737–744.
    1. Brock MV, Alberg AJ, Hooker CM, et al. Risk of subsequent primary neoplasms developing in lung cancer patients with prior malignancies. J Thorac Cardiovasc Surg 2004; 127:1119–1125.
    1. Cho I, An JY, Kwon IG, et al. Risk factors for double primary malignancies and their clinical implications in patients with sporadic gastric cancer. Eur J Surg Oncol 2014; 40:338–344.
    1. Poullis M, Shackcloth M, Page R, et al. Metastatic index of non-small-cell lung cancer and long-term survival. Asian Cardiovasc Thorac Ann 2015; 185–190.
    1. Poullis M, McShane J, Shaw M, et al. Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. Eur J Cardiothorac Surg 2013; 43:919–924.
    1. Fry JS, Lee PN, Forey BA, et al. Is the shape of the decline in risk following quitting smoking similar for squamous cell carcinoma and adenocarcinoma of the lung? A quantitative review using the negative exponential model. Regul Toxicol Pharmacol 2015; 72:49–57.
    1. Koike T, Koike T, Yoshiya K, et al. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg 2013; 146:372–378.
    1. Yamamoto K, Ohsumi A, Kojima F, et al. Long-term survival after video-assisted thoracic surgery lobectomy for primary lung cancer. Ann Thorac Surg 2010; 89:353–359.
    1. Higuchi M, Yaginuma H, Yonechi A, et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage IA non-small cell lung cancer. J Cardiothorac Surg 2014; 9:88.
    1. Vallières E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4:1049–1059.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj